Futura Rises on Erection-Gel Licensing Deal Speculation

Futura Medical Plc (FUM) rose the most in almost two months on speculation that it will announce a licensing agreement on its erection-enhancing product.

Futura rose 11 percent to close at 70.5 pence in London trading, the biggest gain since Nov. 13. The price is the highest since July 12 and gives the Guildford, England-based company a market value of 54.6 million pounds ($87.8 million).

The company is seeking a new partner for CSD500, a gel used inside a condom, after talks with Reckitt Benckiser Group Plc (RB/) collapsed in August. Investors may be anticipating an announcement “over the next quarter,” Chief Executive Officer James Barder said in an interview. He declined to specify when the company might complete a deal.

“We are pleased about the progress being made,” Barder said today by telephone. “We’ve had a lot of interest, and those discussions are progressing.”

Approval of the CE Mark needed to sell CSD500 in Europe is also “on track,” the company said in a statement today. While the board is confident of licensing the product, there is no guarantee of a deal or that the terms will reflect management’s expectations of the produt’s value, Futura said.

To contact the reporter on this story: Makiko Kitamura in London at mkitamura1@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.